Remdesivir & Baricitinib Shortened Recovery Time from COVID-19
As the world rejoiced over the promising results from several COVID-19 vaccine candidates, the United States set a new record of 300,000 coronavirus deaths. This was a stark reminder that some people cannot wait for a vaccine next spring.
The ACTT-2 clinical trial recently investigated the use of both remdesivir and baricitinib, which may help with the recovery of hospitalized COVID-19 patients. The findings now appear in The New England Journal of Medicine.
Benefits of Drug Repurposing
One reason that COVID-19 is so hard to treat is that it has numerous effects on the body. These range ...